About this trial

Single center, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Essential Pro to meet EU Medical Device regulation (MDR) requirements in all the CONSECUTIVE patients treated with Essential Pro.

Eligibility criteria

Qualifiers

Patient treated with Essential Pro according to routine hospital practice and following instructions for use

Informed consent signed

Disqualifiers

Not meet inclusion criteria

Trial design

Treatments tested in this trial

  • Essential pro

Treatment groups

100 Participants
are divided into 1 treatment group

Locations

1
Princess Margaret Hospital Lai Chi Kok Hong Kong

Sponsors and collaborators

Fundación EPIC

Lead sponsor